EUVIMEDEUVIMED entdecken
Open Access

Functional magnetic resonance imaging in schizophrenia: current evidence, methodological advances, limitations and future directions

Aristotle N Voineskos, Colin Hawco, Nicholas H Neufeld, Jessica A Turner, Stephanie H Ameis, Alan Anticevic, Robert W Buchanan, Kristin Cadenhead, Paola Dazzan, Erin W Dickie, Julia Gallucci, Adrienne C Lahti und 5 weitere

World Psychiatry · 2024-02 · 23 (1) · 26-51

DOI: 10.1002/wps.21159 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Psychiatry, online erschienen am 12.01.2024. Verfasst von Aristotle N Voineskos und 16 weiteren Autor:innen. Beteiligte Einrichtung: Campbell Family Mental Health Research Institute and Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada. Die Arbeit wurde bisher 83-mal zitiert (Crossref) und nennt 472 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Functional neuroimaging emerged with great promise and has provided fundamental insights into the neurobiology of schizophrenia. However, it has faced challenges and criticisms, most notably a lack of clinical translation. This paper provides a comprehensive review and critical summary of the literature on functional neuroimaging, in particular functional magnetic resonance imaging (fMRI), in schizophrenia. We begin by reviewing research on fMRI biomarkers in schizophrenia and the clinical high risk phase through a historical lens, moving from case‐control regional brain activation to global connectivity and advanced analytical approaches, and more recent machine learning algorithms to identify predictive neuroimaging features. Findings from fMRI studies of negative symptoms as well as of neurocognitive and social cognitive deficits are then reviewed. Functional neural markers of these symptoms and deficits may represent promising treatment targets in schizophrenia. Next, we summarize fMRI research related to antipsychotic medication, psychotherapy and psychosocial interventions, and neurostimulation, including treatment response and resistance, therapeutic mechanisms, and treatment targeting. We also review the utility of fMRI and data‐driven approaches to dissect the heterogeneity of schizophrenia, moving beyond case‐control comparisons, as well as methodological considerations and advances, including consortia and precision fMRI. Lastly, limitations and future directions of research in the field are discussed. Our comprehensive review suggests that, in order for fMRI to be clinically useful in the care of patients with schizophrenia, research should address potentially actionable clinical decisions that are routine in schizophrenia treatment, such as which antipsychotic should be prescribed or whether a given patient is likely to have persistent functional impairment. The potential clinical utility of fMRI is influenced by and must be weighed against cost and accessibility factors. Future evaluations of the utility of fMRI in prognostic and treatment response studies may consider including a health economics analysis.

Schlagwörter

Stichwörter der Autor:innen

Schizophreniabiomarkersclinical utilitycognitionfunctional magnetic resonance imagingfunctional outcomesnegative symptomsprecision medicinetherapeutic mechanismstreatment response

Autor:innen und Institutionen

  • Campbell Family Mental Health Research Institute and Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada.
  • Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • Department of Psychiatry and Behavioral Health, Wexner Medical Center, Ohio State University, Columbus, OH, USA.
  • Cundill Centre for Child and Youth Depression and McCain Centre for Child, Youth and Family Mental Health, Centre for Addiction and Mental Health, Toronto, ON, Canada.
  • Interdepartmental Neuroscience Program, Yale University, New Haven, CT, USA.
  • Department of Psychiatry, Yale University, New Haven, CT, USA.

Förderung

  • NCATS NIH HHS

Zitieren

APA

Voineskos, A. N., Hawco, C., Neufeld, N. H., Turner, J. A., Ameis, S. H., Anticevic, A., Buchanan, R. W., Cadenhead, K., Dazzan, P., Dickie, E. W., Gallucci, J., Lahti, A. C., Malhotra, A. K., Öngür, D., Lencz, T., Sarpal, D. K., & Oliver, L. D. (2024). Functional magnetic resonance imaging in schizophrenia: current evidence, methodological advances, limitations and future directions. World Psychiatry, 23(1), 26-51. https://doi.org/10.1002/wps.21159

Vancouver

Voineskos AN, Hawco C, Neufeld NH, Turner JA, Ameis SH, Anticevic A, et al. Functional magnetic resonance imaging in schizophrenia: current evidence, methodological advances, limitations and future directions. World Psychiatry. 2024;23(1):26-51. doi:10.1002/wps.21159

BibTeX
@article{Voineskos2024,
  author = {Voineskos, Aristotle N and Hawco, Colin and Neufeld, Nicholas H and Turner, Jessica A and Ameis, Stephanie H and Anticevic, Alan and Buchanan, Robert W and Cadenhead, Kristin and Dazzan, Paola and Dickie, Erin W and Gallucci, Julia and Lahti, Adrienne C and Malhotra, Anil K and Öngür, Dost and Lencz, Todd and Sarpal, Deepak K and Oliver, Lindsay D},
  title = {Functional magnetic resonance imaging in schizophrenia: current evidence, methodological advances, limitations and future directions},
  journal = {World Psychiatry},
  year = {2024},
  volume = {23},
  number = {1},
  pages = {26--51},
  doi = {10.1002/wps.21159}
}
Kostenlos starten →